Transgenomic Q3 Revenues Fall 16 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Wednesday that its sales in the third quarter fell 16 percent year over year.

Total sales for the three months came in at $6.6 million, compared to $7.9 million a year ago. While the Omaha, Neb.-based company saw a change in mix to higher priced lab tests and higher contract revenues associated with a collaboration agreement, it wasn't enough to offset a decrease in laboratory services to $4.1 million from $4.7 million, and a drop in diagnostic tools sales to $2.5 million from $3.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.